CSF1 and neoplasm: There are also concerns regarding the potential harmful effects of FGFR blockade on normal bone remodelling, as AZD4547 inhibits the secretion of RANKL/M-CSF by osteoblasts and differentiation of osteoclasts in the absence of tumour cells.